- 1
- 1 Title: Fecal metaproteomics enables functional characterization of remission in patients with
- 2 inflammatory bowel disease
- 3 Authors:
- 4 Maximilian Wolf^{a,b,1}, Julian Lange^c, Dirk Benndorf^d, Lina Welz^e, Susanna Nikolaus^e, Laura Sievers^e,
- 5 Florian Tran^e, Kay Schallert^f, Patrick Hellwig^{c,g}, Stefan Schreiber^e, Matthias Gunzer^{f,h}, Philip
- 6 Rosenstiel^e, Udo Reichl^{c,g}, Konrad Aden ^{e,2} and Robert Heyer ^{a,f,2}
- 7 a. Multidimensional Omics Analyses group, Faculty of Technology, Bielefeld University,
- 8 Universitätsstrasse 25, 33615 Bielefeld, Germany
- 9 b. Graduate School DILS, Bielefeld Institute for Bioinformatics Infrastructure (BIBI), Bielefeld University,
- 10 Universitätsstrasse 25, 33615 Bielefeld, Germany
- 11 c. Bioprocess Engineering, Otto-von-Guericke University Magdeburg, Universitätsplatz 2,
- 12 39106 Magdeburg, Germany
- 13 d. Applied Biosciences and Process Engineering, Anhalt University of Applied Science, Bernburger Straße
- 14 56, 06366 Koethen, Germany
- 15 e. Institute of Clinical Molecular Biology, Christian-Albrechts University of Kiel, Rosalind-Franklin-Straße
- 16 12, 24105 Kiel, Germany
- 17 f. Leibniz-Institut für Analytische Wissenschaften ISAS e.V., Bunsen-Kirchhoff-Str. 11,
- 18 44139 Dortmund, Germany
- 19 g. Max Planck Institute for Dynamics of Complex Technical Systems, Sandtorstraße 1,
 20 39106 Magdeburg, Germany
- 21 h. Institute for Experimental Immunology and Imaging Center Essen, University Hospital Essen,
- 22 Hufelandstrasse 55, 45147 Essen, Germany
- 23 1. Corresponding Author (maximilian.wolf@uni-bielefeld.de)

24 2. Contributed equally.

25

26 **Short title:** Characterization of IBD remission with metaproteomics

27

- 28 Adress for correspondence: Maximilian Wolf, Multidimensional Omics Analyses group, Faculty of
- 29 Technology, Bielefeld University, , Universitätsstrasse 25, 33615 Bielefeld, Germany (E-Mail:
- 30 maximilian.wolf@uni-bielefeld.de, phone: +49 521 106-2908)
- 31 Conference Presentation: 5th International metaproteomics symposium, Avignon, France

32 Abbreviations:

CD	Crohn's disease
CLCA1	Calcium-activator chloride channel regulator 1
CRP	C-reactive protein
DEF3A	Neutrophil defensin 3
E.C.	Enzyme comission
eMayo	Endoscopic Mayo
FASP	Filter-aided sample preparation
FC	Fecal calprotectin
HBI	Harvey-Bradshaw index
IBD	Inflammatory bowel disease
IL-6	Interleukin 6
KEGG	Kyoto Encyclopedia of Genes and Genomes
LAMP1	Lysosomal-associated membrane protein 1
NET	Neutrophil extracellular trap

PIGR	Polymeric immunoglobulin receptor
PPW	Pentose phosphate pathway
ТСА	Tricarboxylic acid
UC	Ulceratice colitis
VNN1	Pantetheinase

4

34 Abstract

Background: The gut microbiome is an important contributor to the development and the course of inflammatory bowel disease (IBD). While changes in the gut microbiome composition were observed in response to IBD therapy using biologics, studies elucidating human and microbial proteins and pathways in dependence on therapy success are sparse.

39 Methods: Fecal samples of a cohort of IBD patients were collected before and after 14 weeks of treatment 40 with three different biologics. Clinical disease activity scores were used to determine the clinical response 41 and remission. Fecal metaproteomes of remitting patients (n=12) and of non-remitting patients (n=12) 42 were compared before treatment and changes within both groups were assessed over sampling time to 43 identify functional changes and potential human and microbial biomarkers.

44 Results: The abundance of proteins associated with the intestinal barrier, neutrophilic granulocytes, and 45 immunoglobulins significantly decreased in remitting patients. In contrast, an increase of those proteins 46 was observed in non-remitting patients. There were significant changes in pathways of microbial 47 metabolism in samples from patients with remission after therapy. This included, for example, an 48 increased abundance of proteins from butyrate fermentation. Finally, new potential biomarkers for the 49 prediction and monitoring of therapy success could be identified, e.g. human lysosome-associated 50 membrane glycoprotein 1, a cytotoxicity marker, or microbial anthranilate synthase component 2, a part 51 of the tryptophan metabolism.

52 Conclusions: Distinct changes of proteins related to gut inflammation and gut microbiome metabolism
 53 showed whether IBD remission was achieved or not. This suggests that metaproteomics could be a useful
 54 tool for monitoring remission in IBD therapies.

55 Keywords: Clinical trials, Biomarkers, Microbiology

56 **1. Introduction**

57 Crohn's disease (CD) and ulcerative colitis (UC), summarized under the term inflammatory bowel diseases 58 (IBD), are chronic, recurrent inflammations of the intestinal tract that place enormous physical and 59 psychosocial burdens on the patient [1, 2]. IBD has been shown to be linked to the patient's genetics and 60 environmental factors. However, the patient's intestinal microbiome also plays a special role in the 61 etiology [3–6]. The permanent exposure of the intestinal epithelium to diverse microbial antigens requires 62 a fine orchestration of the immune response in the case of pathogen infection, while still exhibiting a 63 tolerance of commensal microorganisms [7]. This is ensured in the intestine of healthy individuals by an 64 intact epithelial barrier as well as a broad spectrum of immunologically active substances, such as 65 cytokines or adhesion molecules. In patients with IBD, the inflammatory response is inappropriate and the 66 epithelial barrier is damaged, which can lead to infiltration of the intestinal tissue with microorganisms 67 and consequent inflammatory cascades [8].

68 Various therapeutic approaches such as drug, surgery, nutritional intervention, and fecal transplantation 69 are used to treat this inflammation and to achieve remission, a medical condition characterized by 70 decreasing severity of disease symptoms and mucosal healing [9]. Typical drugs are small-molecule drugs 71 and biologics. Small molecule drugs, such as thiopurines, aminosalicylates, or steroids, are inexpensive, 72 non-immunogenic molecules, but are characterized by a short half-life and low selectivity and efficacy [10, 73 11]. In contrast, biologics are large complex molecules, in the form of monoclonal antibodies or antibody-74 drug-conjugates, which specifically bind to certain molecules involved in IBD pathogenesis, particularly 75 those that interfere with immune cell communication or migration [12]. Although monoclonal antibodies 76 have a higher half-life, effectiveness, and selectivity, antibodies can be recognized as antigens by the 77 patient's immune system and thus their long-term effectiveness can be severely limited. In addition to the 78 immunogenicity of the antibodies, other factors contribute to widely varying efficacies of treatments in 79 different patients, such as genetic polymorphisms or metabolic potential of the patient's gut microbiome

80 [13–15].

Despite increasing efforts and the introduction of novel targeted therapies in the treatment of IBD (anti-TNF, anti-a₄b₇ integrin, anti-IL12/23, anti-IL23, JAK inhibitors, S1P modulators) the overall long-term disease control is still considerably low at approximately 40% [16].

The early assessment of biomarkers that are associated with a favorable or unfavorable treatment response to biologic therapies might therefore help to guide early treatment decision (e.g. switch treatment class). Huge efforts have been undertaken to investigate the role of the intestinal microbiome as a potential driver of treatment response in IBD. In this context most studies have initially focused on analysis species diversity using 16S analysis, whilst lately metabolic properties (in-silico metabolic modelling [17], fecal metabolomics [18]) have been the focus of investigation.

90

Although the metaproteome reflects the actual proteins expressed in the microbiome and the human proteins in the stool sample and might show a stronger association with the inflammation state as genbased methods [19], there are only very few publications on longitudinal studies of IBD patients using metaproteomic methods compared to a multitude of metagenomic studies [20–24]. Therefore, this study aimed to use metaproteomic approaches to investigate the host and microbial metabolism as well as the abundance of proteins representing the host's immune response, to determine differences between patients who achieved remission with biologics therapy and those who did not.

99 2. Material and Methods

100 Patients and sampling

101 In the course of this study, the 26 patients with IBD, including 13 patients diagnosed with CD and 13 102 patients diagnosed with UC, were treated with three different therapeutic agents (Infliximab: n=7, 103 Vedolizumab: n=9, Olamkizept n=10) at the University Hospital Schleswig Holstein, as described before 104 [13, 25] . At baseline and after 14 weeks of treatment, C-reactive protein (CRP) and Interleukin 6 (IL-6) in 105 the blood, calprotectin and blood leukocytes in the stool of the patients were measured by ELISA. Disease 106 intensity was characterized using the MAYO score for UC and the Harvey-Bradshaw index (HBI) for CD 107 patients. The participants provided paired stool samples at baseline and after 14 weeks of therapy. To 108 inactivate potential pathogenic material during sample processing, 200 µL of 1% Sodium docecyl sulfate 109 (SDS) solution were added to 200 µg of the stool samples and this solution was heated to 99°C for 10 110 minutes.

111 Metaproteomic analysis

112 Metaproteomic analysis was performed according to a previously established workflow [26, 27]. The 113 proteins of the solutions were extracted using phenol in a ball mill. The protein concentration was then 114 determined using the Amido Black assay. Subsequently, 10 µg protein of the samples were tryptically 115 digested (enzyme-substrate ratio 1:100) on a filter according to the filter-aided sample preparation (FASP) 116 protocol [28]. LC/MS-MS measurements were performed using an UltiMate 3000 RSLCnano 117 chromatography system (Thermo Fisher Scientific, Bremen, Germany) with a C18 reversed phase pre-118 column (Acclaim PepMap100 C18, Thermo Fisher Scientific, Bremen, Germany) and a C18 reversed-phase 119 separation column (Acclaim PepMap100 C18, Thermo Fisher Scientific, Bremen, Germany) coupled to a 120 timsTOF mass spectrometer (Bruker Daltonik GmbH, Bremen, Germany). Further details are summarised 121 in Supplementary Note 1. Compass DataAnalysis 5.1 software (Bruker Daltonik GmbH, Bremen, Germany) was used to process and analyze the mass spectra. Using the search engine Mascot™ 2.6 (Matrix Science, 122

123 London, Great Britain) and the following parameters: enzyme trypsin, one missed cleavage, monoisotopic 124 mass, carbamidomethyl as fixed and oxidation as variable modification, ±0.02 Da precursor and ±0.02 Da 125 MS/MS fragment tolerance and a false discovery rate of 1 %, the peptides were annotated with the entries 126 of UniProtKB/SwissProt (16/01/2019) and a metagenome database published by Qin et al. [29], used in a 127 previous IBD study [30]. Identifications of redundant homologous proteins generated by these searches 128 were combined into protein groups (hereafter referred to as metaproteins) based on shared peptides 129 using MetaProteomAnalyzer, version 3.4. Metaproteins without functional or taxonomic annotation were assigned using the BLAST and the UniProtKB/SwissProt database. Blast hits with an e-value <10⁻⁴ were 130 131 used for annotation according to the lowest common ancestor rule. Metaproteins with less than 10 spectra 132 were excluded from the following analysis. Subsequently, the spectral counts of the protein groups were 133 normalized to the total spectral count of the respective sample. Finally, a result matrix additionally 134 consisting of taxonomic annotation, enzyme commission (E.C.) number, Kyoto Encyclopedia of Genes and Genomes (KEGG) orthologies, UniProtKB reference cluster, and UniProt keywords was generated, which 135 136 was used for the analysis. The MS files are available under accession number PXD053257 in the PRIDE 137 Archive.

Orthogonal validation of Lysosomal-associated membrane protein 1 (LAMP1) with independent validation
 cohort using ELISA

For validation of biomarker discovery from metaproteomics experiments, fecale aspirates of n = 58 patients with UC aged 20-80 years were sampled between 2021 and 2023 at the First Medical Department of University Hospital Schleswig-Holstein, Campus Kiel, Germany. All patients provided written informed consent and biomaterial sampling from patients was approved by the local ethics committee of Kiel University (Vote#: B231/98). Fecale aspirates were sampled during colonoscopy by flushing the distal colon with water followed by aspiration of the fluids. Patients were recruited as a broad cross-sectional cohort at different stages of disease activity and displayed an equal distribution of endoscopic Mayo 147 (eMayo) scores (0-3) and complete Mayo scores (0-11). Remission was defined as an endoscopic Mayo 148 Score of ≤ 1 and a complete Mayo score of ≤ 2 . Samples were kept frozen at -80 degrees and measured by 149 ELISA according to the manufacturer (LAMP1: Abcam, ab277464) at the First Medical Department of 150 University Hospital Innsbruck, Austria. Measurements below the detection level were excluded from the 151 final analysis.

152 Statistical analysis

For statistical analysis, R-statistics (version 1.3.1093) was used. Unpaired samples (samples at baseline or week 14 from patients with and without remission) were analyzed applying Wilcoxon rank sum test, paired samples (samples at baseline and week 14 from patients with remission, samples at baseline and week 14 from patients without remission) were analyzed applying Wilcoxon signed rank test using the method "wilcox.test". The visualization with violin plots was realized using the libraries "ggplot2" and "ggstatsplot". Volcano plots were created using Python (version 3.8.13) and the libraries "pandas", "numpy", and "matplotlib".

161 **3. Results**

162 Characteristics of the study cohort

164	In total, 26 patients provided fecal samples before and after 14 weeks of biologics therapy. The therapy
165	with one of three biologics (Infliximab: n=7, Vedolizumab: n=9, Olamkizept n=10) led to an overall
166	significant decrease in clinical disease scores (HBI: from 9.91 ± 7.32 to 4.18 ± 4.78, p-Value 0.042)(Mayo
167	score: from 7.15 ± 2.48 to 3.00 ± 2.99, p-value < 0.001)(Figure 1). As remission was characterized as a Mayo
168	score ≤2 respectively an HBI≤4 and a concentration of serum CRP ≤5 mg/L, 12 out of 26 patients reached
169	by definition a remitting state of the disease, 12 did not achieve remission and 2 patients were in remission
170	during the whole therapy. 19 patients showed an overall response to the therapy. In line with the MAYO
171	and HBI score, the concentration of Calprotectin decreased significantly by 77%, CRP by 73% and blood
172	leucocytes by 33% across all patients. The concentration of IL-6 was also reduced after therapy by 27%,
173	but this difference was not statistically significant (Figure 1).



174

Figure 1. Clinical and blood parameters of individuals with IBD at baseline and after 14 weeks of therapy with Infliximab, Vedolizumab, or Olamkicept. Data are presented as violin plots, displaying the distribution of the data. Boxes depict the inner quartile range, with the median (black line) and mean (red dot). The outer shape clarifies the kernel probability density of the data. The dashed black lines indicate changes in the values for each patient. To analyze differences in paired samples Wilcoxon signed-rank test was used (* p<0.05, ** p<0.01, *** p<0.001). Abbreviations: HBI (Harvey Bradshaw Index), CRP (C-reactive protein), IL-6 (Interleukin-6)

181

182 Metaproteomics analysis

183

To more specifically characterize the developments of the host inflammation and metabolism as well as the gut microbiome due to the induction of remission, we compared the fecal metaproteomes of remitting patients (n=12) at baseline (BL), and after 14 weeks (W14) of biologics therapy. Furthermore, we analyzed the changes in the fecal metaproteomes from patients (n=12) who did not achieve remission throughout

188 the therapy and, to check for possible metaprotein signatures predictive of therapy success, we compared 189 the metaproteomes of the two groups of patients before the therapy started. 190 On average over all measured samples, 10,268 (±2,149) metaproteins were identified and 31 % of spectra 191 were assigned to bacteria, 1 % to archaeal species, and 0.5 % were assigned to viral proteins. Moreover, 192 40 % of spectra were assigned to eukaryotic proteins (Supplementary Table 1). 193 194 195 196 Fecal metaproteome alterations through therapy in patients with remission 197 198 Numerous changes in the fecal metaproteomes of remitting patients (n=12) were observed. 199 The proportion of spectra assigned to human proteins decreased significantly from 15.7 % to 12.8% (p 200 <0.01) after the therapy in remitting patients (Figure 2A). Furthermore, 1,164 proteins were identified with 201 significantly altered abundance (p-value<0.05, Figure 2B). These included human proteins such as 202 immunoglobulin lambda variable 1-44 (p<0.001, fold change W14/BL: 0.52), lactotransferrin (p<0.001, fold 203 change W14/BL: 0.3), progranulin (p<0.001, fold change W14/BL: 0.43), stomatin-like protein 3 (p<0.001, 204 fold change W14/BL: 0.4) or peptidoglycan recognition protein 1 (PGLYRP1, p<0.001, fold change 205 W14/BL: 0.42), which were significantly reduced. In addition, the abundance of various microbial proteins 206 was also altered. The proteins with the lowest p-value included 50S ribosomal protein L7/L12 (p<0.001, 207 fold change W14/BL: 0.31), 3-octaprenyl-4-hydroxybenzoate carboxy-lyase (p<0.001, fold change 208 W14/BL: 0.60), DNA-directed RNA polymerase subunit beta (p<0.001, fold change W14/BL: 0.41), PAN2-209 PAN3 deadenylation complex catalytic subunit (p<0.001, fold change W14/BL: 0.33) and small ribosomal 210 subunit biogenesis GTPase RsgA (p<0.001, fold change W14/BL: 0.32)(Table 1). 211



212

213 Figure 2. Proportion of spectra assigned to human proteins and differentially expressed metaproteins. A: Proportion of spectra 214 assigned to human proteins in samples from non-remitting and remitting patients at baseline and after 14 weeks of therapy 215 (Wilcoxon signed-rank test: ** p < 0.01. B: Volcano plot showing enrichment and depletion of metaproteins in baseline samples 216 from non-remitting patients compared to baseline samples from remitting patients. C: Volcano plot showing enrichment and 217 depletion of metaproteins in samples from remitting patients after 14 weeks of therapy compared to baseline. D: Volcano plot 218 showing enrichment and depletion of metaproteins in samples from non-remitting patients after 14 weeks of therapy compared 219 to baseline. In (B), (C), and (D), red dots describe sequences that have been enriched or depleted by factor 2 with a significance 220 level of p < 0.05, calculated by Wilcoxon signed-rank test (B, C) and Wilcoxon rank sum test (D). The p-values and fold changes 221 depicted in (B), (C), and (D) are shown in Table S2.

222

Table 1. Significantly altered human and microbial metaproteins with lowest p-values (calculated with Wilcoxon signed-rank test) in samples from patients with remission at week 14 compared to baseline. Unknown metaproteins were excluded. The taxonomy column shows the lowest confirmed taxonomic rank. Metaproteins assigned to the kingdom Metazoa were considered

as host (human) metaprotein. Wilcoxon rank sum test was used to analyze differences between unpaired samples (n=24). The

227 function was inferred by UniProt keywords or GO term annotation.

Human	Description	Function	Taxonomy	Average %	Fold change	p-Value
metaproteins (ID)				abundance	(W14/BL)	
8343	Immunoglobulin lambda variable 1-44	Adaptive immunity	Species: Homo Sapiens	3.93 x 10 ⁻¹	0.52	<0.001
10087	Lactotransferrin	Antimicrobial	Phylum: Chordata	1.34 x 10 ⁻¹	0.30	<0.001
12875	Granulins	Cytokine	Class: Mammalia	2.95 x 10 ⁻²	0.43	<0.001
138	Stomatin-like protein 3	signal transduction	Species: Homo Sapiens	8.96 x 10 ⁻²	0.40	<0.001
11321	Peptidoglycan recognition protein 1	Innate immunity	Species: Homo Sapiens	5.49 x 10 ⁻²	0.42	<0.001
Microbial	Description	Function	Taxonomy	Average %	Fold change	n-Value
metaproteins (ID)	Compton	, unclose	abundance		(W14/BL)	p vulue
15670	50S ribosomal protein L7/L12	Ribosomal protein	Species: Persephonella marina	3.42 x 10 ⁻²	0.31	<0.001
17989	3-octaprenyl-4-hydroxybenzoate carboxy-lyase	Ubiquinone biosynthesis	Species: Vibrio vulnificus	1.56 x 10 ⁻²	0.60	<0.001
17075	DNA-directed RNA polymerase subunit beta	Transcription	Species: Clostridium novyi	1.12 x 10 ⁻²	0.41	<0.001
15292	PAN2-PAN3 deadenylation complex catalytic subunit	mRNA processing	Species: Lodderomyces	6.09 x 10 ⁻³	0.33	<0.001
13358	Small ribosomal subunit biogenesis GTPase RsgA	Ribosome biogenesis	Genus: Bacillus	5.16 x 10 ⁻³	0.32	<0.001

228

229 The comparison of functionally grouped proteins showed that intestinal barrier (p=0.034, fold change 230 W14/BL: 0.79), neutrophil granulocytes (p=0.009, fold change W14/BL: 0.56), "other immune cells" 231 (p=0.003, fold change W14/BL: 0.51) and immunoglobulin light chain proteins (p<0.001, fold change 232 W14/BL: 0.71) were significantly reduced in remission patients at week 14, compared to baseline (Figure 233 2 A, B). In contrast, we observed several microbial processes such as butyrate fermentation (p=0.042, fold 234 change W14/BL: 2.76), the pentose phosphate pathway (PPW, p=0.007, fold change W14/BL: 1.79), 235 succinate synthesis (p=0.016, fold change W14/BL: 1.71) and sugar (p=0.003, fold change W14/BL: 1.97) 236 and peptide transport (p=0.029, fold change W14/BL: 2.83), that were significantly increased in patients 237 with clinical remissions (Figure 1C). Furthermore, we observed changes in the abundance of proteins of 238 the blood (p=0.052, fold change W14/BL: 0.33), microbial lactate fermentation (p=0.569, fold change 239 W14/BL: 8.41) or the complement system (p=0.107, fold change W14/BL: 0.30) which however, were not 240 significant.



Figure 3. Overview of the functional assignment of identified metaproteins from patients at baseline and after 14 weeks of therapy. Data from patients who did not achieve remission are displayed in blue, data from patients who achieved remission are displayed in orange. Significant changes are marked with *. Identified metaproteins were functionally assigned to host metaproteins (A), microbial and human hydrolysis enzymes (B), microbial metabolism (C), and microbial transporters (D) (Supplementary Table 3). Data are presented as normalized average spectral abundance. All metaproteins assigned to the kingdom Metazoa were considered as host metaproteins. "Human trypsin" was shown as separated bar in (B) since its abundance was potentially increased due to the trypsin used for tryptic digestion. The Wilcoxon rank sum test was used to analyze differences in independent samples (n = 26, * p < 0.05, ** p < 0.01). The Wilcoxon signed rank test was used to analyze differences in dependent samples (n = 26, * p < 0.05, ** p < 0.01 for patients who achieved remission, n = 26, * p < 0.05, ** p < 0.01 for patients who did not achieve remission). Bar graphs show \pm standard deviation.

250

251 Fecal metaproteome alterations through therapy in patients without remission

252

253	In patients without remission (n=12), the proportion of spectra assigned to human proteins increased non-
254	significantly from 14.8 % to 16.3 % and only 375 metaproteins changed significantly in abundance
255	(p<0.05). Human metaproteins which increased significantly, include LAMP1 (p=0.002, fold change
256	W14/BL: 3.05), polymeric immunoglobulin receptor (PIGR, p=0.005, fold change W14/BL: 1.58),
257	pantetheinase (VNN1, p=0.005, fold change W14/BL: 1.70), calcium-activated chloride channel regulator
258	1 (CLCA1, p=0.007, fold change W14/BL: 1.84) and neutrophil defensin 3 (DEF3A, p=0.007, fold change
259	W14/BL: 2.88). Microbial metaproteins which were significantly altered include e.g., ribosomal RNA large
260	subunit methyltransferase H (p<0.001, fold change W14/BL: 2.76) and anthranilate synthase component
261	2 (p=0.003, fold change W14/BL: 2.56) (Table 2).

262Table 2. Significantly altered human and microbial metaproteins with lowest p-values (calculated with Wilcoxon signed-rank263test) in samples from patients without remission at week 14 compared to baseline. Unknown metaproteins were excluded. The264taxonomy column shows the lowest confirmed taxonomic rank. Metaproteins assigned to the kingdom Metazoa were considered265as host (human) metaprotein. The function was inferred by UniProt keywords or GO term annotation.

Human	Description	Function	Taxonomy	Average %	Fold change	p-Value	
metaproteins (ID)			· · · · ,	abundance	(W14/BL)	(W14/BL)	
12709	Lysosome-associated membrane glycoprotein 1	host-virus interaction	Class: Mammalia	9.25 x 10 ⁻³	3.05	0.002	
8549	Polymeric immunoglobulin receptor	polymeric Ig binding	Class: Mammalia	5.75 x 10 ⁻¹	1.58	0.005	
11174	Pantetheinase	acute inflammatory response	Class: Mammalia	4.69 x 10 ⁻²	1.70	0.005	
102	Calcium-activated chloride channel regulator 1	calcium transport	Species: Homo sapiens	3.80 x 10 ⁻¹	1.84	0.007	
368	Neutrophil defensin 3	Antimicrobial	Order: Primates	1.29 x 10 ⁻¹	2.88	0.007	
Microbial	Description	Eurotion	Taxonomy	Average %	Fold change	n Value	
metaproteins (ID)	Description	Function	Taxonomy	abundance	(W14/BL)	p-value	
14309	Ribosomal RNA large subunit methyltransferase	rRNA processing	Species: Clostridium difficile	7.77 x 10 ⁻³	2.76	<0.001	
15465	Anthranilate synthase component 2	tryptophan biosynthesis	Species: Salmonella enterica	8.41 x 10 ⁻³	2.56	0.003	
44500							
11588	Uncharacterized protein HI_0392	acyltransferase activity	Species: Bacillus subtilis	9.08 x 10 ⁻³	2.01	0.005	
11588	Uncharacterized protein HI_0392 Alpha-monoglucosyldiacylglycerol synthase	acyltransferase activity Carbohydrate metabolism	Species: Bacillus subtilis Species: Streptococcus	9.08 x 10 ⁻³ 1.03 x 10 ⁻²	2.01 2.27	0.005 0.005	

268	Even in patients who did not achieve remission, differences in the metabolic processes and host protein
269	abundance in stool metaproteome were observed after 14 weeks of therapy (Figure 3). Proteins of the
270	intestinal barrier (p=0.035, fold change W14/BL: 1.40), IG-J chains (p=0.017, fold change W14/BL: 2.22)
271	and human carbohydrate metabolism (p=0.011, fold change W14/BL: 1.49) were significantly increased in
272	abundance. An insignificant increase was observed for e.g., immunoglobulin light chains (p=0.850, fold
273	change W14/BL: 1.07) and proteins from neutrophilic granulocytes (p=0.428, fold change W14/BL: 1.14).
274	In contrast, the microbial metabolic pathways of formate fermentation (p=0.013, fold change
275	W14/BL: 0.34) and pyruvate synthesis (p=0.004, fold change W14/BL: 0.50) were significantly decreased,
276	whereas vitamin B12 transport (p<0.001, fold change W14/BL: 1.60) was significantly increased. Human
277	blood (p=0.296, fold change W14/BL: 0.50) and complement system (p=0.266, fold change W14/BL: 0.65)
278	proteins were not significantly decreased.
279	
280	
281	Fecal metaproteome alterations between patients with and without remission at baseline
282	
283	Whereas the proportion of spectra assigned to human proteins was not significantly different at baseline
284	between remitting and non-remitting patients (Figure 2A), a total of 550 metaproteins were significantly
285	altered between patients with and without remission at baseline (p-value < 0.05, Figure 2B). Human
286	proteins that were significantly increased in remission patients included DEF3A (p=0.003, ratio R/NR: 4.37),
287	HLA class II histocompatibility antigen, DR alpha chain (p=0.003, ratio R/NR: 5.27), or CLCA1 (p=0.004, ratio
288	R/NR: 2.74) (Table 3). In contrast, human metaproteins like centromere protein F were significantly
289	increased in non-remitting patients (p=0.002, R/NR: 0.17). Significantly changed microbial proteins

acetyltransferase 2 (p=0.002, R/NR: 0.17) and polyphosphate kinase (p=0.001, only in patients with
Remission).

293

Table 3. Significantly altered human and microbial metaproteins between patients with and without remission at baseline with
 lowest p-Values. Unknown metaproteins were excluded. The taxonomy column shows the lowest confirmed taxonomic rank.
 Metaproteins assigned to the kingdom Metazoa were considered as host (human) metaprotein. Wilcoxon rank sum test was used

to analyze differences between unpaired samples (n=24). The function was inferred by UniProt keywords or GO term annotation.

Human	Description Function		Taxonomy	Average %	Fold change	p-Value
metaproteins (ID)				abundance	(R/NR)	
9938	Double homeobox protein 4-like protein 4	transcription regulation	Species: Homo Sapiens	9.1 x 10 ⁻²	7.65	0.001
23146	Centromere protein F	cell cycle	Species: Homo Sapiens	1.43 x 10 ⁻³	0.17	0.002
368	Neutrophil defensin 3	antimicrobial	Order: Primates	1.79 x 10 ⁻¹	4.37	0.003
17966	HLA class II histocompatibility antigen, DR alpha chain adaptive i		Species: Homo Sapiens	8.36 x 10 ⁻³	5.27	0.003
17342	Calcium-activated chloride channel regulator 1 calcium transport		Class: Mammalia	1.29 x 10 ⁻²	2.74	0.004
Microbial	Description	Function	Taxonomy	Average %	Fold change	p-Value
Microbial metaproteins (ID)	Description	Function	Taxonomy	Average % abundance	Fold change (R/NR)	p-Value
Microbial metaproteins (ID) 8869	Description Riboflavin biosynthesis protein RibBA	Function riboflavin biosynthesis	Taxonomy Superkingdom: Bacteria	Average % abundance 1.65 x 10 ⁻³	Fold change (R/NR) 12.24	p-Value 0.002
Microbial metaproteins (ID) 8869 23145	Description Riboflavin biosynthesis protein RibBA Chloramphenicol acetyltransferase 2	Function riboflavin biosynthesis antibiotic resistance	Taxonomy Superkingdom: Bacteria Species: Escherichia coli	Average % abundance 1.65 x 10 ⁻³ 1.43 x 10 ⁻³	Fold change (R/NR) 12.24 0.17	p-Value 0.002 0.002
Microbial metaproteins (ID) 8869 23145 23148	Description Riboflavin biosynthesis protein RibBA Chloramphenicol acetyltransferase 2 UDP-N-acetylmuramoyl-tripeptideD-alanyl-D-alanine	Function riboflavin biosynthesis antibiotic resistance cell wall biogenesis/degradation	Taxonomy Superkingdom: Bacteria Species: Escherichia coli Species: Synechocystis sp. PCC 6803	Average % abundance 1.65 x 10 ⁻³ 1.43 x 10 ⁻³ 1.04 x 10 ⁻²	Fold change (R/NR) 12.24 0.17 0.10	p-Value 0.002 0.002 0.003
Microbial <u>metaproteins (ID)</u> 8869 23145 23148 20508	Description Riboflavin biosynthesis protein RibBA Chloramphenicol acetyltransferase 2 UDP-N-acetylmuramoyl-tripeptideD-alanyl-D-alanine Polyphosphate kinase	Function riboflavin biosynthesis antibiotic resistance cell wall biogenesis/degradation kinase	Taxonomy Superkingdom: Bacteria Species: <i>Escherichia coli</i> Species: <i>Synechocystis sp. PCC 6803</i> Class: Gammaproteobacteria	Average % abundance 1.65 × 10 ⁻³ 1.43 × 10 ⁻³ 1.04 × 10 ⁻² 2.03 × 10 ⁻¹	Fold change (R/NR) 12.24 0.17 0.10 only in patients	p-Value 0.002 0.002 0.003 0.003

298

299

300 To disentangle host and microbial processes, we independently assessed metaproteomes attributed to 301 humans or microbiota (Figure 3). Concerning the functional processes of the gut microbiome, the 302 abundance of proteins involved in vitamin 12 transport was significantly higher (p=0.014, ratio R/NR: 1.86) 303 and the abundance of proteins of microbial methanogenesis (p=0.003, ratio R/NR: 0.34) was found 304 significantly lower in patients who achieved remission. (Figure 3C). Other non-significantly different 305 processes in terms of their protein abundance included bacteriocin transport (p=0.059, ratio R/NR: 3.88), 306 glycerol metabolism (p=0.159, ratio R/NR: 0.26) or succinate metabolism (p=0.143, ratio R/NR 0.74). 307 No processes to which human proteins were grouped, were significantly altered, except for proteins

308 assigned to carbohydrate hydrolysis (p=0.024, ratio R/NR:). Proteins of neutrophil granulocytes (p=0.143,

- ratio R/NR: 1.28) and proteins of mucosal functions (p=0.060, ratio R/NR: 1.42) were present in lower
- 310 abundance in patients who did not achieve remission.
- 311
- 312
- 313 Identification of disease-specific biomarker candidates for monitoring the success of IBD therapy
- 314

315 For the identification of disease-specific biomarker candidates for monitoring or predicting the success of 316 IBD therapy, only metaproteins with an average relative abundance of at least 0.01% in at least one patient 317 group (R-BL, R-W14, NR-BL, NR-W14) were considered. The most promising human and microbial 318 biomarkers, in our opinion, for which a pathogenesis contribution can be traced, are shown in Figure 4. 319 The first microbial biomarker shown, anthranilate synthase component 2 (Meta-Protein 15465, Salmonella 320 enterica) increases significantly during therapy in patients who did not achieve remission (NR-BL/NR-W14: 321 p<0.005). Furthermore, 3-octaprenyl-4-hydroxybenzoate carboxy-lyase (Meta-Protein 17989, Vibrio 322 vulnificus, R-BL/R-W14: p<0.001) was found significantly decreased and glutamate dehydrogenase (Meta-323 Protein 1031, Unknown Superkingdom, R-BL/R-W14: p=0.002) was found significantly increased in 324 remitting patients.

The abundance of the human proteins S100-A8 (R-BL/R-W14: p=0.012) and CRP (R-BL/R-W14: p=0.036) decreased in patients with remission in the course of therapy. Significant changes were also observed for the human protein DEF3A (R-BL/NR-BL: p=0.001, R-BL/R-W14: p=0.021, NR-BL/NR-W14: p=0.007). Only in patients without remission does the human protein LAMP1 (NR-BL/NR-W14: p=0.003) increase. In contrast, the PGLYRP1 decreases significantly in patients with remission (R-BL/R-W14: p=0.001). Likewise, the protein Granulins decreases significantly in remission patients (R-BL/R-W14: p<0.001).

331 In a first attempt to validate the finding from the metaproteomic biomarker discovery, LAMP1, as a 332 probable indicator for the failure of the therapy, was measured with ELISAs in fecal washes of UC patients

- 333 (Figure S1). A large but statistically insignificant (p=0.069) increase in the abundance of LAMP1 in was
- found in patients, who were not in remission.
- 335

336



Figure 4. Panel of potential marker metaproteins as violin plots. Relative abundance of the marker metaproteins in fecal samples
 from IBD patients who achieved remission (R) and IBD patients who did not achieve remission (NR) at baseline and after 14 weeks
 of biologics therapy. The means are illustrated as red dots. P-values were calculated with Wilcoxon signed-rank test (between

- 341 timepoints of remitting or non-remitting patients) and Wilcoxon rank sum test (between remitting and non-remitting patients at
- 342 baseline).

344 4. Discussion

345 Fecal metaproteome alterations through therapy in patients with remission

With the help of the analysis of the fecal metaproteomes from patients who achieved remission, a large number of changes in the course of therapy could be determined. These are obvious by the large number of significantly altered proteins and the significantly decreased proportion spectra assigned to human proteins in the course of the therapy, which was described previously to be indicative of disease activity [31].

351 The changes indicate on the one hand that the immune response of this group of patients has decreased 352 and on the other hand that proteins of the microbial metabolism are present in increased abundance.

353 The significantly decreased abundance of intestinal barrier proteins, as well as the decrease in blood 354 proteins, indicate an increased integrity of the epithelial layer of the intestine [32, 33]. Furthermore, the 355 decreased abundance of proteins from neutrophilic granulocytes is a sign of less translocation to the gut 356 of these immune cells [34, 35], which are an important driver of inflammation in IBD. The significantly 357 decreased human proteins, immunoglobulins, lactotransferrin, or progranulin have already been 358 associated with IBD [36–38]. Their decline in abundance suggests an ameliorated disease course. The 359 significant decrease in PGLYRP1 also indicates less dysbiosis with the gut microbiome, as this protein, 360 which is also part of neutrophil extracellular traps (NETs), recognizes bacterial cell wall structures and 361 initiates the inflammatory response [39, 40].

The reduced dysbiosis is also recognizable in the significantly increased abundance of microbial metabolic pathways, such as the PPW, the tricarboxylic acid cycle /succinate metabolism, or butyrate fermentation. The PPW is crucial for biomass increase and growth and an increased abundance of its enzymes may indicate a prosperous intestinal microbiome [41], further supported by increased transport of sugars and peptides. The increased metabolism of succinate, which promotes the release of pro-inflammatory

367 cytokines, could prevent the accumulation of it in the feces, which is a phenomenon observed in IBD 368 inflammation, and thereby further improve growth conditions [42]. Finally, butyrate fermentation in 369 particular is of great importance for the well-being of the patient, as butyrate serves as an energy source 370 for colonocytes and has great anti-inflammatory potential [43, 44]. The increased synthesis of butyrate 371 can also serve as an indicator of the stability of remission [45].

372

373 Fecal metaproteome alterations through therapy in patients without remission

374 Based on the altered processes and proteins of the patients who did not achieve remission, a strongly deviating reaction of the intestinal immune system and the gut microbiome to the therapy can be stated. 375 376 Immune-relevant processes and protein groups, like proteins from neutrophils or immunoglobulins, which 377 showed a clear decline in patients with remission, are not significantly decreased in this group of patients. 378 The increase of immunoglobulin light chain and immunoglobulin J-chain could also be a hint at the 379 formation of anti-drug antibodies, which are a major cause of therapy failure in biologics treatment [46], 380 The increased formation of microbiome targeting immunoglobulins was observed in active IBD [47], so 381 th95e target of those antibodies needs to be elucidated. Nevertheless, the secretion of immunoglobulins 382 into the gut lumen depends on the PIGR [48], which is one of the most significantly increased proteins in 383 non-remitting patients, supporting the hypothesis of an increased antibody response.

Other individual proteins, that have been described as the IBD susceptibility locus, such as VNN1 [49], or that are associated with the immune response in IBD, like LAMP1 [50], are present in significantly increased abundance after therapy. These findings indicate an ongoing inflammation whose character has changed due to the induction of therapy. The reason for an ongoing inflammation could be the expansion of apoptosis-resistant immune cells, which was observed in non-responding IBD patients in reaction to biologics therapy. Immune modulatory therapies have also been shown to increase LAMP1 abundance

[51], which is often used to measure degranulation and cytotoxic potential of cytotoxic lymphocytes [52]. 390 391 Increased cytotoxicity was observed in IBD patients in association with increased apoptosis in the intestinal 392 mucosa [53]. Identification of epithelial proteins like VNN1, PIGR, and CLCA1 among the most significantly 393 increased proteins and the significant increase in the abundance of intestinal barrier proteins in general, 394 would support this hypothesis. Increased abundance of proteins from neutrophilic granulocytes, especially 395 antimicrobial DEF3A, could be a reaction to increased microbial evasion due to barrier defects. As microbial 396 metabolite synthesis, like butyrate fermentation or formate synthesis, which is significantly decreased in 397 non-remitting patients, potentially limits the cytotoxic effects of immune cells [54, 55], the lack of a healthy 398 microbiome could contribute to therapy failure.

399 Nevertheless, there are some changes in the metaproteome of these patients that indicate at least a 400 slightly beneficial response to therapy. Proteins of microbial vitamin B12 transport were significantly 401 increased, which could indicate a reduced dysbiosis of the gut microbiome [56]. Furthermore, the 402 abundance of human blood proteins was halved. As fecal hemoglobin was previously identified as a 403 biomarker for intestinal inflammation [57], the decline of blood proteins could indicate at least a minor 404 amelioration of the disease. This is also supported by the reduction of proteins coupled to the complement 405 system. As this pathway is part of the innate immune response and the response to microbial-associated 406 molecular patterns this could also be a hint to less pronounced microbial dysbiosis.

407

408 Fecal metaproteome alterations between patients with and without remission at baseline

As there are no reliable biomarkers to predict the success of a therapy and clinicians often empirically try different drugs to achieve remission [58], our final comparison aimed to identify metaprotein patterns,

411 that are likely to predict the success of biologics therapy before the therapy started.

In healthy individuals, the defense against pathogenic organisms in the human intestine takes place through a balanced reaction of the innate and adaptive immune system [59]. Increased immune response is seen at the onset of therapy, particularly in patients who subsequently achieve remission. Proteins of the innate immune system, such as neutrophil DEF3A, and the adaptive immune system, such as HLA class II histocompatibility antigen, are increased significantly in remitting patients. A high amount of alphadefensins was indeed described as a prediction of therapy response in IBD therapy before [60].

418 Furthermore, ROS are an important instrument of the intestinal immune response. But they represent a 419 double-edged sword in the pathogenesis of IBD, as a fine-tuned regulation is necessary to eliminate 420 pathogens, but at the same time avoid killing commensal microorganisms and damage tissue. The 421 increased abundance of microbial proteins that synthesize the antioxidants riboflavin and polyphosphate 422 in patients, who achieve remission suggests an active contribution of the gut microbiome to tissue 423 protection in these individuals [61]. In contrast, microbial processes that act as a sink for the anti-424 inflammatory molecule hydrogen [62], such as methanogenesis and glycerol metabolism, are more 425 prevalent in patients who do not achieve remission. These changes indicate an imbalance of the immune 426 response and the microbiome concerning oxidative stress, which possibly promotes the depletion of 427 beneficial microorganisms and tissue damage, which seems to extend during the therapy, as stated above. 428 This hypothesis is underlined by the increased abundance of blood proteins in patients without remission. 429 Furthermore, the increased abundance of chloramphenicol acetyltransferase 2 in non-remitting patients 430 hints at an involvement of the gut resistome, which is expanded in many diseases [63].

For other significantly changed proteins like Double homeobox protein 4-like protein 4, a transcription
factor or centromere protein F, a marker for poor prognosis in cancer [64, 65], no connection to IBD or gut
immunity is described underlining the knowledge gaps still existing.

In general, predictive biomarkers are described as dependent on used biologic [66], which renders the
general assessment of predictive biomarkers hard in the present study. Nevertheless, as microbiome

fitness and human protein biomarkers are included in nearly all predictive models, the prediction of therapy success using metaproteomics appears feasible. Taking into account other omics levels, like metabolomics, and a personalized approach, thereby benefitting from knowledge about e.g., individual polymorphisms of a patient, would further improve prediction potential [67].

440 Identification of disease-specific biomarkers

To be able to predict the success of therapy before medication or to assess the effectiveness of ongoing therapy, the search for biomarkers is a central topic of ongoing research. As we opted to identify markers, which are present in easily detectable abundances, we only considered metaproteins with an average relative abundance of at least 0.01% in at least one patient group (R-BL, R-W14, NR-BL, NR-W14).

In particular, fecal calprotectin (FC) and CRP have been investigated in a large number of studies using antibody-based methods such as ELISA [68–70]. Although their use is often hindered by disadvantages such as a lack of specificity [71], we considered them as biomarkers in our cohort. Both show a significant decrease in patients with remission, but there is no significant difference between patients with and without remission at baseline to predict therapy success. Taken together with the observation of outlying individuals, the need for more specific biomarkers or a panel of biomarkers is obvious.

The earlier-mentioned increased antimicrobial potential in patients without remission is supported by the consideration of DEF3A. Furthermore, the data presented in Figure 4 regarding the abundance of the proteins of neutrophil granulocytes are depicted reliably, so the protein seems to be suitable as a marker protein for the invasion of this type of leukocyte. The violin plot (Figure 4) further implies that a high amount of DEF3A, which has broad antimicrobial activity [72], in a patient's feces predicts therapy success at baseline, whereas a low amount could be proof of a successful therapy after termination. Interestingly, high DEF3A was also evaluated as a positive predictive marker in cancer immunotherapy [73].

A marker for reduced dysbiosis in remission patients could also be the human PGLYRP1. Since this protein is involved in antigen recognition [40], the decrease in this protein may indicate reduced invasion of intestinal tissue by microorganisms. The significant decrease in granulins also indicates a decrease in immune response and inflammation in remission patients.

In contrast, the significant increase in LAMP1, an essential protein of natural killer cell cytotoxicity [74], may indicate a change in the nature of inflammation in patients without remission. This means physicians may have to change the therapeutic strategy, for example to antibodies against NKG2D, which induces cytolytic natural killer cells and T-cells upon interaction with stress-related molecules [75]. The validation of LAMP1 with an ELISA also showed a higher abundance in non-remitting patients, but the increase was not significant. Nevertheless, the strong elevation in distinct patients showed the relevance of the protein for specific individuals supporting a precision medicine approach to the treatment of IBD patients.

469 As all human markers depicted in Figure 4 are also described in other malignancies [73, 76–80], their 470 specificity in IBD has to be evaluated further. Since microbial dysbiosis and associated functional and 471 taxonomic differences are hallmarks of IBD, there are also many attempts to discover microbial biomarkers 472 for disease monitoring or responsiveness to therapies. The significant differences in the microbial 473 biomarkers proposed in Figure 4 show, that they are suitable for disease monitoring. Markers for the 474 different development of microbial metabolism in patients with and without remission could be 475 anthranilate synthase component 2 (Meta-Protein 15465, Salmonella enterica), which is involved in of the 476 tryptophan metabolism and quorum sensing [81]. An increased tryptophan metabolism is under 477 investigation to aggravate disease activity in IBD patients [82]. Furthermore, anthranilate has antimicrobial 478 potential and by increasing in patients who did not achieve remission, the antimicrobial milieu in these 479 patients could be further worsened. Furthermore, the species the metaprotein is annotated to, Salmonella 480 enterica, is described to benefit from inflammation, to overcome colonization resistance and to play a role 481 in the onset of IBD [83, 84].

482 In contrast a decreasing abundance of 3-octaprenyl-4-hydroxybenzoate carboxylyase (Meta-Protein 483 17989, Vibrio vulnificus), which catalyzes an intermediate step in the biosynthesis of ubiquinone, an 484 antioxidant and tested as supplement in inflammatory diseases, could serve as a marker of less oxidative 485 stress and a more hospitable environment for microorganisms. A similar sign of regrowth of a beneficial 486 gut flora could be glutamate dehydrogenase (Meta-Protein 1031, Unknown Superkingdom), which has 487 great importance for microbes in gut colonization and is the most abundant metaprotein found in fecal 488 samples from healthy individuals [85, 86]. Nevertheless, as the gut microbiome underlies huge 489 interindividual and intraindividual changes, finding a single microbial marker protein remains a challenging 490 task, and a panel of marker proteins or the functional assessment of the microbiome might be more 491 promising.

492

493 Despite the ability of metaproteomics to characterize the induced changes in the remission of IBD patients 494 in contrast to non-remitting patients, the present study has limitations. Due to the small number of study 495 participants, the power of the statistical data analysis is limited. Furthermore, the field of participants is 496 quite heterogeneous with regard to their disease. In the evaluation, neither the type of disease (UC, CD) 497 or its local occurrence nor the type of therapeutic agent was considered. Due to the different mechanisms 498 of action of the drugs, different changes in the gastrointestinal microbiome are to be expected [87], 499 leading to specific metaproteome patterns especially between patients treated with different biologics. 500 This could minimalize the observations on the microbial aspects of the analysis. Larger clinical panels, 501 taking into account the different biologics and disease subtypes, to evaluate the differences identified here 502 would be useful.

Furthermore, the influence of environmental influences, e.g. changes in the patient's diet in the course of
therapy, on the metaproteome of the study participants is difficult to assess, which could make the already
large interindividual differences even more significant.

506 Moreover, many identified meta-proteins, some of which changed significantly in the course of therapy, 507 could not be annotated. Analyzing different metaproteomic data sets may hold potential to help in 508 annotation of these potentially disease relevant features [88].

509

510 Fecal metaproteomics enabled us to monitor the success of biological-based IBD therapy deduced from 511 proteins linked with inflammation and bacterial metabolisms, showing its potential for clinical application. 512 Remitting patients showed a decrease in immune functions, in particular, decreased abundance of 513 neutrophilic proteins and an increased abundance of several microbial functions, like butyrate synthesis. 514 The fecal metaproteomes of patients with an unsuccessful therapy were marked by increased abundance 515 of immunoglobulin proteins and signs of cytotoxicity and tissue damage. Furthermore, we proposed 516 several new potential biomarker candidates, which could also be of interest for further antibody-based 517 monitoring of IBD therapy.

519 **5. Funding**

- 520 This research was supported by the German Research Foundation (Deutsche Forschungsgemeinschaft,
- 521 DFG) under Germany's Excellence Strategy –EXC2167-Project ID 390884018 "Precision Medicine in Chronic
- 522 Inflammation" (K.A.) the RU5042-miTarget (to K.A.), the EKFS (Clinician Scientist Professorship, K.A.), the
- 523 BMBF (eMED Juniorverbund "Try-IBD" 01ZX1915A).
- 524
- 525 6. Acknoledgements
- 526 Not applicable.

527 7. Data Availability Statement

- 528 The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via
- 529 the PRIDE partner repository with the dataset identifier PXD053257.
- 530 Reviewer access details
- 531 Log in to the PRIDE website using the following details:
- 532 Project accession: PXD053257
- 533 Token: ZUI01Soinr2K
- Alternatively, reviewer can access the dataset by logging in to the PRIDE website using the following
- 535 account details:
- 536 Username: reviewer_pxd053257@ebi.ac.uk
- 537 Password: z6IsKunGzcvs
- 538 8. Conflicts of Interest:
- 539 Not applicable.

541 **9. Author contributions:**

- Conceptualization: R.H., K.A.
- Experiments metaproteomics: J.L., P.H.
- ELISA experiments: L.W., S.N., F.T., S.T.
- Data evaluation: J.L., M.W., L.W., S.N., F.T., S.T.
- Bioinformatics: K.S., J.L., M.W.
- Graphical abstract: K.S.
- Supervision: R.H., K.A.
- critical revision of the manuscript: D.B., M.G., R.H., K.A., K.S., U.R., P.R.
- writing—original draft: M.W.
- writing—review and editing: R.H., K.A.

552

553 All authors have read and agreed to the published version of the manuscript.

555 **References**

- 556 [1] Yu YR, Rodriguez JR. Clinical presentation of Crohn's, ulcerative colitis, and indeterminate colitis:
- 557 Symptoms, extraintestinal manifestations, and disease phenotypes. Semin Pediatr Surg 2017; 26(6):
- 558 349-55
- 559 [https://doi.org/10.1053/j.sempedsurg.2017.10.003][PMID: 29126502]
- 560 [2] Bernabeu P, Belén-Galipienso O, van-der Hofstadt C, et al. Psychological burden and quality of life in
- newly diagnosed inflammatory bowel disease patients. Front Psychol 2024; 15: 1334308
 [https://doi.org/10.3389/fpsyg.2024.1334308][PMID: 38348263]
- 563 [3] Benoni C, Nilsson A. Smoking habits in patients with inflammatory bowel disease. A case-control
- 564
 study.
 Scand
 J
 Gastroenterol
 1987;
 22(9):
 1130–6

 565
 [https://doi.org/10.3109/00365528708991970][PMID: 3423738]
- 566 [4] Glassner KL, Abraham BP, Quigley EMM. The microbiome and inflammatory bowel disease. J Allergy
- 567 Clin Immunol 2020; 145(1): 16–27

568 [https://doi.org/10.1016/j.jaci.2019.11.003][PMID: 31910984]

569 [5] Lange KM de, Moutsianas L, Lee JC, *et al.* Genome-wide association study implicates immune
570 activation of multiple integrin genes in inflammatory bowel disease. Nat Genet 2017; 49(2): 256–61

571 [https://doi.org/10.1038/ng.3760][PMID: 28067908]

- 572[6] Ye BD, McGovern DPB. Genetic variation in IBD: progress, clues to pathogenesis and possible clinical573utility.ExpertRevClinImmunol2016;12(10):1091–107
- 574 [https://doi.org/10.1080/1744666X.2016.1184972][PMID: 27156530]
- 575[7] Wu H-J, Wu E. The role of gut microbiota in immune homeostasis and autoimmunity. Gut Microbes5762012;3(1):4–14
- 577 [https://doi.org/10.4161/gmic.19320][PMID: 22356853]

578	[8] Wei J, Feng J.	Signaling pathway	s associated wit	h inflammatory	bowel disease. Ree	cent Pat Inflamm
579	Allergy	Drug	Discov	2010;	4(2):	105–17
580	[https://doi.o	rg/10.2174/187221	310791163071]	[PMID: 2000189	9]	
581	[9] Cai Z, Wang S	, Li J. Treatment of	Inflammatory B	owel Disease: A	Comprehensive Re	eview. Front Med
582	(Lausanne)		2021;		8:	765474
583	[https://doi.o	rg/10.3389/fmed.2	021.765474][PN	1ID: 34988090]		
584	[10] Liu J, Di B, Xu I	L. Recent advance	s in the treatmer	nt of IBD: Targets	, mechanisms and r	related therapies.
585	Cytokine	Growth	Factor	Rev	2023; 71-7	72: 1–12
586	[https://doi.o	rg/10.1016/j.cytogf	fr.2023.07.001][PMID: 37455149]	
587	[11] Na S-Y, Moon	W. Perspectives on	Current and No	vel Treatments f	or Inflammatory Bo	owel Disease. Gut
588	Liver	20)19;	13(6):	604–16
589	[https://doi.o	rg/10.5009/gnl190	19][PMID: 31195	5433]		
590	[12] Yamamoto-Fu	urusho JK, Parra-H	olguín NN. Eme	erging therapeur	tic options in infla	ammatory bowel
591	disease.	World J	Gastroer	nterol 20	21; 27(48):	8242–61
592	[https://doi.o	rg/10.3748/wjg.v27	7.i48.8242][PMII	D: 35068868]		
593	[13] Aden K, Rehm	ian A, Waschina S, e	<i>et al.</i> Metabolic I	Functions of Gut	Microbes Associat	e With Efficacy of
594	Tumor Necros	sis Factor Antagonis	sts in Patients W	ith Inflammator	y Bowel Diseases.	Gastroenterology
595	2019;		157(5)	:		1279-1292.e11
596	[https://doi.o	rg/10.1053/j.gastrc	0.2019.07.025][P	MID: 31326413]		
597	[14] Ben-Horin S,	Chowers Y. Review	article: loss of r	esponse to anti	-TNF treatments in	Crohn's disease.
598	Aliment	Pharmacol	Ther	2011;	33(9):	987–95
599	[https://doi.o	rg/10.1111/j.1365-	2036.2011.0461	2.x][PMID: 2136	6636]	
600	[15] Netz U, Carte	er JV, Eichenberger	MR, et al. Gen	etic polymorphis	sms predict respon	ise to anti-tumor
601	necrosis fact	or treatment in (Crohn's disease	. World J Gast	troenterol 2017;	23(27): 4958–67
602	[https://doi.o	rg/10.3748/wjg.v23	3.i27.4958][PMII	D: 28785150]		

- [16] Mishra N, Aden K, Blase JI, *et al.* Longitudinal multi-omics analysis identifies early blood-based
 predictors of anti-TNF therapy response in inflammatory bowel disease. Genome Med 2022; 14(1):
- 605 110
- 606 [https://doi.org/10.1186/s13073-022-01112-z][PMID: 36153599]
- 607 [17] Bauer E, Thiele I. From metagenomic data to personalized in silico microbiotas: predicting dietary
- 610 [18] Vich Vila A, Hu S, Andreu-Sánchez S, et al. Faecal metabolome and its determinants in inflammatory
- 611 bowel disease. Gut 2023; 72(8): 1472–85
- 612 [https://doi.org/10.1136/gutjnl-2022-328048][PMID: 36958817]
- 613 [19] Mills RH, Vázquez-Baeza Y, Zhu Q, et al. Evaluating Metagenomic Prediction of the Metaproteome in
- a 4.5-Year Study of a Patient with Crohn's Disease. mSystems 2019; 4(1)
 [https://doi.org/10.1128/mSystems.00337-18][PMID: 30801026]
- [20] Ding NS, McDonald JAK, Perdones-Montero A, et al. Metabonomics and the Gut Microbiome
 Associated With Primary Response to Anti-TNF Therapy in Crohn's Disease. J Crohns Colitis 2020;
 14(8): 1090–102
- 619 [https://doi.org/10.1093/ecco-jcc/jjaa039][PMID: 32119090]

620 [21] Effenberger M, Reider S, Waschina S, et al. Microbial Butyrate Synthesis Indicates Therapeutic Efficacy

- 621
 of Azathioprine in IBD Patients. J Crohns Colitis 2021; 15(1): 88–98

 622
 [https://doi.org/10.1093/ecco-jcc/jjaa152][PMID: 32687146]
- [22] Lloyd-Price J, Arze C, Ananthakrishnan AN, *et al.* Multi-omics of the gut microbial ecosystem in
 inflammatory bowel diseases. Nature 2019; 569(7758): 655–62
 [https://doi.org/10.1038/s41586-019-1237-9][PMID: 31142855]

- 626 [23] Schierova D, Roubalova R, Kolar M, et al. Fecal Microbiome Changes and Specific Anti-Bacterial 627 Response in Patients with IBD during Anti-TNF Therapy. Cells 2021; 10(11) 628 [https://doi.org/10.3390/cells10113188][PMID: 34831411]
- [24] Schirmer M, Franzosa EA, Lloyd-Price J, et al. Dynamics of metatranscription in the inflammatory
 bowel disease gut microbiome. Nat Microbiol 2018; 3(3): 337–46
 [https://doi.org/10.1038/s41564-017-0089-z][PMID: 29311644]
- 632 [25] Schreiber S, Aden K, Bernardes JP, et al. Therapeutic Interleukin-6 Trans-signaling Inhibition by
- 633 Olamkicept (sgp130Fc) in Patients With Active Inflammatory Bowel Disease. Gastroenterology 2021;

2354-2366.e11

- 634 160(7):
- 635 [https://doi.org/10.1053/j.gastro.2021.02.062][PMID: 33667488]
- 636 [26] Sydor S, Dandyk C, Schwerdt J, et al. Discovering Biomarkers for Non-Alcoholic Steatohepatitis
- 637 Patients with and without Hepatocellular Carcinoma Using Fecal Metaproteomics. Int J Mol Sci 2022;
- 638 23(16)
- 639 [https://doi.org/10.3390/ijms23168841][PMID: 36012106]
- 640 [27] Biemann R, Buß E, Benndorf D, et al. Fecal Metaproteomics Reveals Reduced Gut Inflammation and
- 641 Changed Microbial Metabolism Following Lifestyle-Induced Weight Loss. Biomolecules 2021; 11(5)
 642 [https://doi.org/10.3390/biom11050726][PMID: 34066026]
- [28] Heyer R, Schallert K, Büdel A, *et al.* A Robust and Universal Metaproteomics Workflow for Research
 Studies and Routine Diagnostics Within 24 h Using Phenol Extraction, FASP Digest, and the
 MetaProteomeAnalyzer. Front Microbiol 2019; 10: 1883
 [https://doi.org/10.3389/fmicb.2019.01883][PMID: 31474963]
- [29] Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic
 sequencing. Nature 2010; 464(7285): 59–65
 [https://doi.org/10.1038/nature08821][PMID: 20203603]

- 650 [30] Lehmann T, Schallert K, Vilchez-Vargas R, et al. Metaproteomics of fecal samples of Crohn's disease
- 651 and Ulcerative Colitis. J Proteomics 2019; 201: 93-103
- 652 [https://doi.org/10.1016/j.jprot.2019.04.009][PMID: 31009805]
- 653 [31] Zhang X, Deeke SA, Ning Z, et al. Metaproteomics reveals associations between microbiome and 654 intestinal extracellular vesicle proteins in pediatric inflammatory bowel disease. Nat Commun 2018; 2873
- 655 9(1):
- 656 [https://doi.org/10.1038/s41467-018-05357-4][PMID: 30030445]
- 657 [32] Szymanska E, Wierzbicka A, Dadalski M, Kierkus J. Fecal Zonulin as a Noninvasive Biomarker of 658 Intestinal Permeability in Pediatric Patients with Inflammatory Bowel Diseases-Correlation with 659 Disease Activity and Fecal Calprotectin. J Clin Med 2021; 10(17) 660 [https://doi.org/10.3390/jcm10173905][PMID: 34501351]
- 661 [33] Fu Y, Wang L, Xie C, et al. Comparison of non-invasive biomarkers faecal BAFF, calprotectin and FOBT
- in discriminating IBS from IBD and evaluation of intestinal inflammation. Sci Rep 2017; 7(1): 2669 662
- 663 [https://doi.org/10.1038/s41598-017-02835-5][PMID: 28572616]
- 664 [34] Guerrant RL, Araujo V, Soares E, et al. Measurement of fecal lactoferrin as a marker of fecal 665 leukocytes. Clin Microbiol 1992; 30(5): 1238-42 J 666 [https://doi.org/10.1128/jcm.30.5.1238-1242.1992][PMID: 1583125]
- 667 [35] Yadav SK, Ito N, Mindur JE, et al. Fecal Lcn-2 level is a sensitive biological indicator for gut dysbiosis 668 and intestinal inflammation in multiple sclerosis. Front Immunol 2022; 13: 1015372 669 [https://doi.org/10.3389/fimmu.2022.1015372][PMID: 36341389]
- 670 [36] Dai J, Liu W-Z, Zhao Y-P, Hu Y-B, Ge Z-Z. Relationship between fecal lactoferrin and inflammatory 671 bowel disease. Scand J Gastroenterol 2007; 42(12): 1440-4 [https://doi.org/10.1080/00365520701427094][PMID: 17852860] 672

- [37] Wei F, Zhang Y, Jian J, et al. PGRN protects against colitis progression in mice in an IL-10 and TNFR2
- 674
 dependent
 manner.
 Sci
 Rep
 2014;
 4:
 7023
- 675 [https://doi.org/10.1038/srep07023][PMID: 25387791]
- [38] Bourgonje AR, Roo-Brand G, Lisotto P, et al. Patients With Inflammatory Bowel Disease Show IgG
- 677 Immune Responses Towards Specific Intestinal Bacterial Genera. Front Immunol 2022; 13: 842911
- 678 [https://doi.org/10.3389/fimmu.2022.842911][PMID: 35693832]
- [39] Cho JH, Fraser IP, Fukase K, et al. Human peptidoglycan recognition protein S is an effector of
 neutrophil-mediated innate immunity. Blood 2005; 106(7): 2551–8
 [https://doi.org/10.1182/blood-2005-02-0530][PMID: 15956276]
- [40] Dziarski R, Gupta D. The peptidoglycan recognition proteins (PGRPs). Genome Biol 2006; 7(8): 232
 [https://doi.org/10.1186/gb-2006-7-8-232][PMID: 16930467]
- [41] Rashida Z, Laxman S. The pentose phosphate pathway and organization of metabolic networks
 enabling growth programs. Current Opinion in Systems Biology 2021; 28: 100390
 [https://doi.org/10.1016/j.coisb.2021.100390]
- 687 [42] Wei Y-H, Ma X, Zhao J-C, Wang X-Q, Gao C-Q. Succinate metabolism and its regulation of host-microbe
- 688
 interactions.
 Gut
 Microbes
 2023;
 15(1):
 2190300
- 689 [https://doi.org/10.1080/19490976.2023.2190300][PMID: 36946592]
- [43] Canani RB, Di Costanzo M, Leone L, Pedata M, Meli R, Calignano A. Potential beneficial effects of
 butyrate in intestinal and extraintestinal diseases. World J Gastroenterol 2011; 17(12): 1519–28
- 692 [https://doi.org/10.3748/wjg.v17.i12.1519][PMID: 21472114]
- [44] Donohoe DR, Garge N, Zhang X, et al. The microbiome and butyrate regulate energy metabolism and
 autophagy in the mammalian colon. Cell Metab 2011; 13(5): 517–26
 [https://doi.org/10.1016/j.cmet.2011.02.018][PMID: 21531334]

- [45] Buffet-Bataillon S, Bouguen G, Fleury F, Cattoir V, Le Cunff Y. Gut microbiota analysis for prediction of
 clinical relapse in Crohn's disease. Sci Rep 2022; 12(1): 19929
- 698 [https://doi.org/10.1038/s41598-022-23757-x][PMID: 36402792]
- [46] Marsal J, Barreiro-de Acosta M, Blumenstein I, Cappello M, Bazin T, Sebastian S. Management of Non-
- response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease.
- 701
 Front
 Med
 (Lausanne)
 2022;
 9:
 897936
- 702 [https://doi.org/10.3389/fmed.2022.897936][PMID: 35783628]
- 703 [47] Masu Y, Kanazawa Y, Kakuta Y, et al. Immunoglobulin subtype-coated bacteria are correlated with the 704 activity inflammatory bowel disease. Sci Rep 2021; 16672 disease of 11(1): 705 [https://doi.org/10.1038/s41598-021-96289-5][PMID: 34404881]
- [48] Turula H, Wobus CE. The Role of the Polymeric Immunoglobulin Receptor and Secretory
 Immunoglobulins during Mucosal Infection and Immunity. Viruses 2018; 10(5)
 [https://doi.org/10.3390/v10050237][PMID: 29751532]
- [49] Gensollen T, Bourges C, Rihet P, *et al.* Functional polymorphisms in the regulatory regions of the VNN1
 gene are associated with susceptibility to inflammatory bowel diseases. Inflamm Bowel Dis 2013;
- 711 19(11):

2315–25

- 712 [https://doi.org/10.1097/MIB.0b013e3182a32b03][PMID: 23949622]
- [50] Jin L, Li L, Hu C, *et al.* Integrative Analysis of Transcriptomic and Proteomic Profiling in Inflammatory
 Bowel Disease Colon Biopsies. Inflamm Bowel Dis 2019; 25(12): 1906–18
 [https://doi.org/10.1093/ibd/izz111][PMID: 31173627]
- [51] Muharam R, Febri RR, Prabowo KA, Bustami A, Mansur IG. Increased Levels of CD107a and
 Intracellular Cytokines in IL-2 Stimulated PBMCs from Endometriosis Patients. Int J Inflam 2021; 2021:
- 718 5760959
- 719 [https://doi.org/10.1155/2021/5760959][PMID: 34616540]

720 [52] Sudworth A, Dai K-Z, Vaage JT, Kveberg L. Degranulation Response in Cytotoxic Rat Lymphocytes 721 Measured with Novel CD107a Antibody. Front Immunol 2016; 7: 572 а 722 [https://doi.org/10.3389/fimmu.2016.00572][PMID: 28003815] 723 [53] Souza HSP, Tortori CJA, Castelo-Branco MTL, et al. Apoptosis in the intestinal mucosa of patients with 724 inflammatory bowel disease: evidence of altered expression of FasL and perforin cytotoxic pathways. 725 Int J Colorectal Dis 2005; 20(3): 277-86 726 [https://doi.org/10.1007/s00384-004-0639-8][PMID: 15503066] [54] Zaiatz-Bittencourt V, Jones F, Tosetto M, et al. Butyrate limits human natural killer cell effector 727 728 function. 2023; 2715 Sci Rep 13(1): 729 [https://doi.org/10.1038/s41598-023-29731-5][PMID: 36792800] 730 [55] Wenzel TJ, Gates EJ, Ranger AL, Klegeris A. Short-chain fatty acids (SCFAs) alone or in combination 731 regulate select immune functions of microglia-like cells. Mol Cell Neurosci 2020; 105: 103493 732 [https://doi.org/10.1016/j.mcn.2020.103493][PMID: 32333962] 733 [56] Kundra P, Geirnaert A, Pugin B, Morales Martinez P, Lacroix C, Greppi A. Healthy adult gut microbiota 734 sustains its own vitamin B12 requirement in an in vitro batch fermentation model. Front Nutr 2022; 735 9: 1070155 736 [https://doi.org/10.3389/fnut.2022.1070155][PMID: 36532531] 737 [57] Kato J, Hiraoka S, Nakarai A, Takashima S, Inokuchi T, Ichinose M. Fecal immunochemical test as a 738 biomarker for inflammatory bowel diseases: can it rival fecal calprotectin? Intest Res 2016; 14(1): 5-739 14 740 [https://doi.org/10.5217/ir.2016.14.1.5][PMID: 26884729] 741 [58] Moss AC. Approach to Treatment Failure in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y) 360-3 742 2022; 18(6): 743 [PMID: 36398141]

- 744 [59] Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and
- 745
 disease.
 Nat
 Rev
 Immunol
 2009;
 9(5):
 313–23
- 746 [https://doi.org/10.1038/nri2515][PMID: 19343057]
- [60] Kanmura S, Uto H, Numata M, *et al.* Human neutrophil peptides 1-3 are useful biomarkers in patients
 with active ulcerative colitis. Inflamm Bowel Dis 2009; 15(6): 909–17
 [https://doi.org/10.1002/ibd.20854][PMID: 19107772]
- [61] Segawa S, Fujiya M, Konishi H, *et al.* Probiotic-derived polyphosphate enhances the epithelial barrier
 function and maintains intestinal homeostasis through integrin-p38 MAPK pathway. PLoS One 2011;
 6(8): e23278
- 753 [https://doi.org/10.1371/journal.pone.0023278][PMID: 21858054]
- [62] Tian Y, Zhang Y, Wang Y, et al. Hydrogen, a Novel Therapeutic Molecule, Regulates Oxidative Stress,
- 755
 Inflammation, and Apoptosis.
 Front
 Physiol
 2021;
 12:
 789507

 756
 [https://doi.org/10.3389/fphys.2021.789507][PMID: 34987419]
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 10:
 1
- [63] Fredriksen S, Warle S de, van Baarlen P, Boekhorst J, Wells JM. Resistome expansion in diseaseassociated human gut microbiomes. Microbiome 2023; 11(1): 166
 [https://doi.org/10.1186/s40168-023-01610-1][PMID: 37507809]
- [64] Landberg G, Erlanson M, Roos G, Tan EM, Casiano CA. Nuclear autoantigen p330d/CENP-F: A marker
 for cell proliferation in human malignancies. Cytometry 1996; 25(1): 90–8
 [https://doi.org/10.1002/(SICI)1097-0320(19960901)25:1<90::AID-CYTO10>3.0.CO;2-P]
- [65] Zhuo Y-J, Xi M, Wan Y-P, et al. Enhanced expression of centromere protein F predicts clinical
 progression and prognosis in patients with prostate cancer. Int J Mol Med 2015; 35(4): 966–72
 [https://doi.org/10.3892/ijmm.2015.2086][PMID: 25647485]
- [66] Caenepeel C, Falony G, Machiels K, et al. Dysbiosis and Associated Stool Features Improve Prediction
- of Response to Biological Therapy in Inflammatory Bowel Disease. Gastroenterology 2024; 166(3):

- 768 483–95
- 769 [https://doi.org/10.1053/j.gastro.2023.11.304][PMID: 38096956]
- 770 [67] Stevens TW, Matheeuwsen M, Lönnkvist MH, et al. Systematic review: predictive biomarkers of
- therapeutic response in inflammatory bowel disease-personalised medicine in its infancy. Aliment
- 772
 Pharmacol
 Ther
 2018;
 48(11-12):
 1213–31
- 773 [https://doi.org/10.1111/apt.15033][PMID: 30378142]
- [68] Schoepfer AM, Beglinger C, Straumann A, Trummler M, Renzulli P, Seibold F. Ulcerative colitis:
 correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C reactive protein, and blood leukocytes. Inflamm Bowel Dis 2009; 15(12): 1851–8
- 777 [https://doi.org/10.1002/ibd.20986][PMID: 19462421]
- [69] D'Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic
 lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18(12): 2218–24
 [https://doi.org/10.1002/ibd.22917][PMID: 22344983]
- 781 [70] Anindita B, Sugihartono T, Miftahussurur M, et al. High levels of fecal calprotectin and C-reactive 782 protein in patients with colitis. J Med Life 2023; 16(1): 48-51 783 [https://doi.org/10.25122/jml-2021-0311][PMID: 36873123]
- 784 [71] Nowak JK, Kalla R, Satsangi J. Current and emerging biomarkers for ulcerative colitis. Expert Rev Mol
- 785
 Diagn
 2023;
 23(12):
 1107–19
- 786 [https://doi.org/10.1080/14737159.2023.2279611][PMID: 37933807]
- 787 [72] Cunliffe RN. Alpha-defensins in the gastrointestinal tract. Mol Immunol 2003; 40(7): 463–7
- 788 [https://doi.org/10.1016/s0161-5890(03)00157-3][PMID: 14568393]
- 789 [73] Berghmans E, Jacobs J, Deben C, et al. Mass Spectrometry Imaging Reveals Neutrophil Defensins as
- 790 Additional Biomarkers for Anti-PD-(L)1 Immunotherapy Response in NSCLC Patients. Cancers (Basel)

12(4)

- 791 2020;
- 792 [https://doi.org/10.3390/cancers12040863][PMID: 32252405]

medRxiv preprint doi: https://doi.org/10.1101/2024.07.02.24309587; this version posted July 3, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

- 793 [74] Krzewski K, Gil-Krzewska A, Nguyen V, Peruzzi G, Coligan JE. LAMP1/CD107a is required for efficient
- perforin delivery to lytic granules and NK-cell cytotoxicity. Blood 2013; 121(23): 4672–83
- 795 [https://doi.org/10.1182/blood-2012-08-453738][PMID: 23632890]
- [75] Vadstrup K, Bendtsen F. Anti-NKG2D mAb: A New Treatment for Crohn's Disease? Int J Mol Sci 2017;
- 797 18(9)
- 798 [https://doi.org/10.3390/ijms18091997][PMID: 28926962]
- [76] Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of
 cancer. Crit Rev Clin Lab Sci 2011; 48(4): 155–70
 [https://doi.org/10.3109/10408363.2011.599831][PMID: 22035340]
- [77] Dang Q, Zhou H, Qian J, *et al.* LAMP1 Overexpression Predicts for Poor Prognosis in Diffuse Large Bcell Lymphoma. Clin Lymphoma Myeloma Leuk 2018; 18(11): 749–54
 [https://doi.org/10.1016/j.clml.2018.07.288][PMID: 30082222]
- [78] Klupp F, Kahlert C, Franz C, *et al.* Granulin: An Invasive and Survival-Determining Marker in Colorectal
 Cancer Patients. Int J Mol Sci 2021; 22(12)
- 807 [https://doi.org/10.3390/ijms22126436][PMID: 34208547]
- [79] Schnell A, Huang L, Regan BML, et al. Targeting PGLYRP1 promotes antitumor immunity while
 inhibiting autoimmune neuroinflammation. Nat Immunol 2023; 24(11): 1908–20
 [https://doi.org/10.1038/s41590-023-01645-4][PMID: 37828379]
- [80] Shabani F, Farasat A, Mahdavi M, Gheibi N. Calprotectin (S100A8/S100A9): a key protein between
 inflammation and cancer. Inflamm Res 2018; 67(10): 801–12
 [https://doi.org/10.1007/s00011-018-1173-4][PMID: 30083975]
- [81] Palmer GC, Jorth PA, Whiteley M. The role of two Pseudomonas aeruginosa anthranilate synthases in
 tryptophan and quorum signal production. Microbiology (Reading) 2013; 159(Pt 5): 959–69
 [https://doi.org/10.1099/mic.0.063065-0][PMID: 23449919]

- [82] Nikolaus S, Schulte B, Al-Massad N, et al. Increased Tryptophan Metabolism Is Associated With Activity
- 818
 of
 Inflammatory
 Bowel
 Diseases.
 Gastroenterology
 2017;
 153(6):
 1504-1516.e2

 819
 [https://doi.org/10.1053/j.gastro.2017.08.028][PMID:
 28827067]
- 820 [83] Schultz BM, Paduro CA, Salazar GA, et al. A Potential Role of Salmonella Infection in the Onset of
- 821
 Inflammatory
 Bowel
 Diseases.
 Front
 Immunol
 2017;
 8:
 191

 822
 [https://doi.org/10.3389/fimmu.2017.00191][PMID: 28293241]
- 823 [84] Stecher B, Robbiani R, Walker AW, et al. Salmonella enterica serovar typhimurium exploits
- 824 inflammation to compete with the intestinal microbiota. PLoS Biol 2007; 5(10): 2177–89
- 825 [https://doi.org/10.1371/journal.pbio.0050244][PMID: 17760501]
- [85] Kolmeder CA, Been M de, Nikkilä J, et al. Comparative metaproteomics and diversity analysis of human
- 827 intestinal microbiota testifies for its temporal stability and expression of core functions. PLoS One
- 828 2012; 7(1): e29913
- 829 [https://doi.org/10.1371/journal.pone.0029913][PMID: 22279554]
- 830 [86] Girinathan BP, Braun S, Sirigireddy AR, Espinola-Lopez J, Govind R. Correction: Importance of
- 831 Glutamate Dehydrogenase (GDH) in Clostridium difficile Colonization In Vivo. PLoS One 2016; 11(10):
- 832 e0165579
- 833 [https://doi.org/10.1371/journal.pone.0165579][PMID: 27768767]

[87] Ruszkowski J, Daca A, Szewczyk A, Dębska-Ślizień A, Witkowski JM. The influence of biologics on the

- 835 microbiome in immune-mediated inflammatory diseases: A systematic review. Biomed Pharmacother
- 836 2021; 141: 111904
- 837 [https://doi.org/10.1016/j.biopha.2021.111904][PMID: 34328113]
- 838 [88] Sun Z, Ning Z, Figeys D. The Landscape and Perspectives of the Human Gut Metaproteomics. Mol Cell
- 839Proteomics2024;23(5):100763
- 840 [https://doi.org/10.1016/j.mcpro.2024.100763][PMID: 38608842]
- 841



TNF-α: Tumor necrosis factor alpha; IL-6: Interleukin 6; DEFA3: Neutrophil defensin 3; CLCA1: Calcium-activated chloride channel regulator 1; LAMP1: Lysosome-associated membrane glycoprotein 1; PIGR: Polymeric immunoglobulin receptor ; VNN1: Pantetheinase. Created in BioRender.com